Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $122
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $124 to $122.
Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $124 to $122.